<?xml version="1.0" encoding="UTF-8"?>
<p id="par0125">In conclusion, we believe that to optimally exploit its multiple biological activities against COVID-19 pandemic, low-dose, intermittent IFN-I treatment schedules should be used in the early stages of infection to compensate for virus-induced IFN-impairment or IFN-deficiency in the frail population, thus accelerating virus clearance and avoiding the progression to the severe forms of COVID-19.</p>
